Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab switch study in previously treated neovascular age-related macular degeneration
ACTRN12623000215628Phase 4Not yet recruiting
- Sponsor
- Cureos
- Start
- Mar 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of faricimab in exudative macular degeneration, sponsored by Cureos. Primary endpoint: Change from baseline in best-corrected visual acuity at Week 52. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ACTRN12623000215628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000215628.